Full Breakdown
GLP-1 Weight-Loss Drugs Linked to Declines in Physical Activity, New Study Finds
6/16/2026, 12:05:26 AM
Study Overview: Reduced Steps and Exercise After GLP-1 Initiation
Researchers presented data at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, showing that adults with obesity who began treatment with GLP-1 receptor agonists—semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, or dulaglutide—recorded fewer daily steps and less moderate-to-vigorous physical activity (MVPA). The analysis used Fitbit recordings from the NIH All of Us Research Program.
Context: GLP-1 Agonists, Weight Loss, and Muscle Concerns
GLP-1 drugs are widely prescribed for obesity because they promote substantial weight loss. Prior literature has highlighted that these agents can also reduce lean muscle mass, raising concerns about metabolic rate and long-term health benefits. The prevailing assumption has been that weight loss naturally encourages greater mobility; the new findings challenge that view.
Principal Researchers and Institutions
The study was led by Dr Sajana Maharjan, M.D., of HSHS St. John’s Hospital in Springfield, Illinois. Commentary on clinical implementation was provided by Dr Mir Ali, M.D., medical director of the MemorialCare Surgical Weight-Loss Center at Orange Coast Medical Center in Fountain Valley, California. Data were drawn from the NIH All of Us Research Program, which links electronic health records with wearable-device metrics.
Quantitative Findings
- Cohort: 753 adults with obesity (78.6 % women; mean age 52.7 years).
- Baseline activity: 5,047 steps/day; 28 minutes MVPA/day.
- Post-initiation activity: 4,487 steps/day (-560 steps) and 22 minutes MVPA/day (-6 minutes).
- Subgroup trends: Largest declines observed in men and participants reporting joint or musculoskeletal pain.
- Non-modifiers: Age, heart-failure history, and prior stroke did not significantly alter the activity reduction.
Clinical Implications
The reduction in daily movement coincides with documented loss of lean muscle mass among GLP-1 users. Diminished muscle can lower resting metabolic rate, potentially compromising weight-maintenance goals and overall health. Researchers therefore argue that structured exercise must be integrated into GLP-1 treatment protocols rather than treated as optional.
Official Statements & Recommendations
Study investigators emphasized that the observed activity decline disproves the notion that weight loss automatically increases physical activity. They recommend prescribing a minimum of 30 minutes of aerobic and resistance exercise five days per week, with flexibility to split sessions. Dr Ali highlighted that even brief walking bouts confer benefit and that tailored programs are especially needed for male patients and those with musculoskeletal discomfort.
Criticism, Limitations, and Data Gaps
The analysis is observational and retrospective, relying on a self-selected sample of wearable-device users. Findings have not yet undergone peer-review, and causality cannot be established. Researchers acknowledge the need for prospective trials to determine whether targeted exercise interventions can mitigate muscle loss and sustain weight-loss outcomes.
Verbatim Quotes
- “Exercise Cannot Be an Afterthought "While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise.” — Dr Sajana Maharjan, M.D., HSHS St. John’s Hospital
- “The findings reinforce that exercise cannot be optional for people taking these medications.” — Dr Sajana Maharjan, M.D.
- “People need targeted interventions that encourage physical activity alongside medication for obesity," Maharjan said.” — Dr Sajana Maharjan, M.D.
- “The goal is 30 minutes of exercise per day, five days a week; even walking provides significant benefits. This can be broken into smaller segments if 30 minutes at once is not feasible. Ideally, a combination of aerobic exercise and resistance training is best for preserving muscle,” — Dr Mir Ali, M.D., MemorialCare Surgical Weight-Loss Center
Future Directions
The authors call for clinical trials that embed structured physical-activity programs within GLP-1 therapy, aiming to assess whether such interventions preserve muscle mass and improve long-term weight-loss maintenance.
